A

Armata Pharmaceuticals Inc
AMEX:ARMP

Watchlist Manager
Armata Pharmaceuticals Inc
AMEX:ARMP
Watchlist
Price: 6.16 USD 14.07% Market Closed
Market Cap: 224.3m USD

Armata Pharmaceuticals Inc
Accounts Payable

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Armata Pharmaceuticals Inc
Accounts Payable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Payable CAGR 3Y CAGR 5Y CAGR 10Y
A
Armata Pharmaceuticals Inc
AMEX:ARMP
Accounts Payable
$1.5m
CAGR 3-Years
-27%
CAGR 5-Years
1%
CAGR 10-Years
1%
Abbvie Inc
NYSE:ABBV
Accounts Payable
$33.6B
CAGR 3-Years
13%
CAGR 5-Years
12%
CAGR 10-Years
15%
Gilead Sciences Inc
NASDAQ:GILD
Accounts Payable
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Accounts Payable
$19.6B
CAGR 3-Years
154%
CAGR 5-Years
76%
CAGR 10-Years
34%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Accounts Payable
$4B
CAGR 3-Years
217%
CAGR 5-Years
106%
CAGR 10-Years
48%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Accounts Payable
$903.8m
CAGR 3-Years
19%
CAGR 5-Years
15%
CAGR 10-Years
24%
No Stocks Found

Armata Pharmaceuticals Inc
Glance View

Market Cap
223m USD
Industry
Biotechnology

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company is headquartered in Marina Del Rey, California and currently employs 72 full-time employees. The firm is focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. The company has developed care therapies, including the multidrug-resistant or superbug strains of bacteria. The firm is a developer of phage therapeutics, which are positioned to address the growing worldwide threat of antibiotic-resistant bacterial infections. The company is developing and advancing its lead clinical phage candidate for Pseudomonas aeruginosa. The firm is also developing a phage product candidate for Staphylococcus aureus for the treatment of staphylococcus aureus bacteremia. The company has phage development to target other indications, including non-cystic fibrosis bronchiectasis, prosthetic joint infections and hospitalized pneumonia. Its product candidates are AP-PA02, AP-PA03 and AP-SA02.

ARMP Intrinsic Value
HIDDEN
Show

See Also

What is Armata Pharmaceuticals Inc's Accounts Payable?
Accounts Payable
1.5m USD

Based on the financial report for Jun 30, 2025, Armata Pharmaceuticals Inc's Accounts Payable amounts to 1.5m USD.

What is Armata Pharmaceuticals Inc's Accounts Payable growth rate?
Accounts Payable CAGR 10Y
1%

Over the last year, the Accounts Payable growth was -55%. The average annual Accounts Payable growth rates for Armata Pharmaceuticals Inc have been -27% over the past three years , 1% over the past five years , and 1% over the past ten years .

Back to Top